Project Grant R01CA305145
Award Date 6/23/26
Completion Date 5/31/31
Dollars Obligated $621K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Mayo Clinic Jacksonville a $498,582 Project Grant (CFDA 93.396: Cancer Biology Research) effective June 1, 2026, through May 31, 2031, to conduct fundamental research on acetylation's role in modulating T cell receptor (TCR) signaling. The research aims to overcome T cell exhaustion and improve the efficacy of cancer immunotherapy by investigating SIRT2 abrogation as a mechanism to enhance TCR signaling through increased...
- Federal Grant Award Summary Mayo Clinic received a $667,710 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on March 20, 2026, for a project titled "Blood-Based Tumor and Immune Markers for Risk Stratification and Monitoring Treatment Response in Oligometastatic Prostate Cancer." The award extends through February 28, 2031, and will be performed at Mayo Clinic's facility in Rochester, Minnesota. The project delivers...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Project Grant Award Summary Mayo Clinic received a $415,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a completion date of April 30, 2028. The grant supports research to improve treatment sensitivity through Spleen Tyrosine Kinase (SYK) targeting using novel translational models of uveal melanoma (UM), the most common primary adult intraocular malignancy. This research addresses a...
- Federal Grant Award Summary Mayo Clinic received a $954,256 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded August 18, 2025, with completion expected July 31, 2030. This research initiative applies germline and somatic genetic analysis to elucidate glioma risk factors and improve patient outcomes. The project leverages genome-wide association studies (GWAS) identifying 30 germline variants associated with adult...
- Federal Grant Award Summary The National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant totaling $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period June 1, 2026 through May 31, 2028. The research focuses on fragment-based targeting of epithelial-to-mesenchymal transition (EMT)-mediated resistance in epidermal growth factor receptor (EGFR)-mutant lung cancer. The project utilizes fragment-like chemical...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $410,545 to The Research Foundation For The State University of New York under the Cancer Treatment Research program (CFDA 93.395) for a Project Grant effective May 1, 2026 through April 30, 2028. The award supports research assessing the role of efflux transport mechanisms, pharmacokinetics, and systems pharmacology in monomethyl auristatin E (MMAE)-induced neurotoxicity associated with antibody-drug conjugate (ADC)...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $687,593 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on May 12, 2026, with completion targeted for April 30, 2031. The award funds fundamental cancer biology research investigating cysteine acquisition and utilization mechanisms in lung adenocarcinoma. The research will deliver scientific insights into how tumor cells...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded Beckman Research Institute of The City of Hope a $736,457 Project Grant on June 26, 2026, with an ultimate completion date of May 31, 2029. The award supports research and development of small molecule inhibitors targeting protein-protein interactions within the ERKS axis (comprising EphrinB, RGS3, KIF20A, and SEPT7 proteins) as a novel differentiation therapy for...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1.098 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on August 13, 2025, with a completion date of April 30, 2030. The funded research focuses on understanding the biological mechanisms controlling CD8+ tumor-infiltrating lymphocytes (TILs) and their progression through various functional states, including...